Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem cell transplant may be an effective treatment for anaplastic large cell lymphoma.

PURPOSE: This clinical trial is studying how well combination chemotherapy followed by stem cell transplant works in treating young patients with progressive or relapsed anaplastic large cell lymphoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
• Treatments: Antilymphocyte Serum; Busulfan; Carboplatin; Carmustine; Cyclosporine; Cyclosporins; Cytarabine; Dexamethasone; Etoposide; Etoposide phosphate; Idarubicin; Ifosfamide; Leucovorin; Levoleucovorin; Lomustine; Melphalan; Methotrexate; Mitoxantrone; Prednisolone; Thiotepa; Vinblastine; Vindesine

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed anaplastic large cell lymphoma (ALCL)

• Progressive disease OR first relapse

• No second or subsequent relapse of ALCL

• Slides available for national central pathology review

• Availability of 1 of the following (for allogeneic stem cell transplantation only):

• HLA-identical matched sibling donor

• 10/10 HLA-matched nonsibling donor (related or unrelated)

• 9/10 HLA-matched nonsibling donor (1-antigen-mismatched related or unrelated donor)

• < 9/10 HLA-mismatched donor (related or unrelated)

• Stem cells may be obtained from unmanipulated bone marrow or peripheral blood stem cells after filgrastim (G-CSF) stimulation

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Adequate hepatic, renal, and cardiac function

• No HIV infection or AIDS

• No severe immunodeficiency

• No other prior malignancy

• No pre-existing disease or condition prohibiting study treatment

PRIOR CONCURRENT THERAPY:

• At least 2 months since prior chemotherapy or radiotherapy

• No significant pretreatment for first relapse

• No prior organ transplantation

• No concurrent participation in another clinical trial